|
|
Profile
|
Delegates :
Nobuyuki Arakawa |
|
Incorporated :
October 8 , 2020 |
Paid in Capital :
510 Million yen Including capital reserve |
Employees :
12 人 |
Address :
Entrepreneur Lab, South Research Bldg., the University of Tokyo 7-3-1 Hongo, Bunkyo-ku TOKYO
〒113-8485
|
TEL/FAX :
+81-50-3612-7767 / |
URL：
https://celaidtx.com/en/ |
Attachment :
|
Mission/Background :
Celaid Therapeutics Inc. is a startup born out of the University of Tokyo and University of Tsukuba with proprietary technology for selective ex vivo HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products in cell therapy for hematologic disease, ex vivo HSC gene therapy for genetic disorders, and angiogenesis for ischemic disease. |
|
Technology & Business
|
1.Pipeline Business
Hematopoietic stem cell transplantation (HSCT) is the only cure for hematological and immunological diseases. Current allogeneic HSCT has issues like securing enough HSCs, waiting for HLA donor matching, and acute/chronic GvHD after HSCT. Celaid’s allogeneic HSC products address these unmet needs by offering better HLA-matched HSCs, safer and more effective treatments for blood and immunodeficiency diseases.
2.Platform Business
Celaid’s HSC platform can selectively expand undifferentiated HSCs in vitro from cord blood, peripheral blood, and other sources. This platform is expected to be applicable to various cell and gene therapies, including ex vivo HSC gene therapies and iPSC-derived immune cells. Celaid has initiated collaborations with startups and pharmaceutical companies globally to develop these next-generation therapies. Through these collaborations, we aim to license the platform tailored to the specific needs of each cell and gene therapy product.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|